Comparison 2. Prostaglandins compared with placebo/standard care: subgroup analyses.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 All‐cause mortality	11		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1.1 Prostaglandins versus placebo	7	534	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.61, 1.40]
2.1.2 Prostaglandins versus standard care	4	237	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.29, 1.87]
2.2 Liver retransplantation	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.2.1 Prostaglandins versus placebo	3	289	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.49, 2.62]
2.2.2 Prostaglandins versus standard care	3	179	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.20, 2.46]
2.3 Primary non‐function	7		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.3.1 Prostaglandins versus placebo	4	407	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.29, 1.70]
2.3.2 Prostaglandins versus standard care	3	217	Risk Ratio (M‐H, Random, 95% CI)	0.19 [0.02, 1.64]
2.4 Acute kidney failure requiring dialysis	5		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.4.1 Prostaglandins versus placebo	4	398	Risk Ratio (M‐H, Random, 95% CI)	0.43 [0.23, 0.81]
2.4.2 Prostaglandins versus standard care	1	79	Risk Ratio (M‐H, Random, 95% CI)	0.38 [0.11, 1.29]